QURE
uniQure N.V.
$26.45
-5.50%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (76%)
Insider Activity0B / 8S
Insider Net $-$1.7M
Reddit Sentiment50° Neutral
SEC Reports9
Press Releases1
Recent Activity
Jun 3, 2026
SEC
Director Jack Kaye filed a Form 144 notice of intent to sell 2,645 ordinary shares of uniQure N.V., valued at approximat
144 — Impact 2/10
Jun 3, 2026
Insider
Kaye Jack sold 2,645 shares
Director @ $16.04 ($42.4K)
Jun 3, 2026
Insider
Kaye Jack sold 2,645 shares
Director @ $30.01 ($79.4K)
Jun 3, 2026
Insider
Kaye Jack sold 2,645 shares
Director @ $0.00 ($0.00)
May 15, 2026
short_volume
Short Volume: QURE — 63.0% short (0.4M / 0.6M)
Short: 364,070 | Exempt: 0 | TRF Vol: 578,324 | Short Ratio: 63.0% | Off-exchange volume (dark pool
May 5, 2026
SEC
uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and revenue of $3.6M, below t
PRESS-RELEASE — Impact 6/10
May 5, 2026
SEC
uniQure reported Q1 2026 revenue of $3.6M (up from $1.6M YoY) and a net loss of $53.5M ($0.85/share), wider than the $43
8-K — Impact 6/10
Mar 2, 2026
Press
uniQure reported financial results for 2025, showing a revenue decline to $16.1 million and a reduced net loss of $199.0
Impact 6/10
Price Targets
$38.81
+46.7% upside
Strong Buy
Current $26.45
Low $13.79
Median $34.80
High $93.57
11 analysts
$13.79
$93.57
Analyst Ratings
6Strong Buy
10Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 30, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Apr 20, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
| Mar 23, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| Mar 11, 2026 | Mizuho | UPGRADE | Neutral → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next FY | $-2.44 ▼ -4.5% | $-3.39 — $-0.33 | 19% YoY | 10 |
| Current FY | $-2.99 ▼ -0.5% | $-3.54 — $-2.57 | -2% YoY | 10 |
| Current Q | $-0.72 ▲ +5.7% | $-0.80 — $-0.65 | -20% YoY | 10 |
| Next Q | $-0.75 ▲ +5.0% | $-0.92 — $-0.64 | 37% YoY | 10 |
Latest Reports
NEUTRAL
144
2/10
Director Jack Kaye filed a Form 144 notice of intent to sell 2,645 ordinary shares of uniQure N.V., valued at approximat
Jun 3, 2026
BEARISH
PRESS-RELEASE
6/10
uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and revenue of $3.6M, below t
May 5, 2026
MIXED
Press
6/10
uniQure reported financial results for 2025, showing a revenue decline to $16.1 million and a reduced net loss of $199.0
Mar 2, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Kaye Jack | M | $42.4K |
| Jun 3, 2026 | Kaye Jack | SELL | $79.4K |
| Jun 3, 2026 | Kaye Jack | M | $0.00 |
| May 8, 2026 | Abi-Saab Walid | M | $139.8K |
| May 8, 2026 | Abi-Saab Walid | SELL | $627.5K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
6 unique insiders with 8 transactions. Net insider value: -$1.7M ($0.00 bought, $1.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Kaye Jack | Director | M | 2,645 | $16.04 | $42.4K |
| Jun 3, 2026 | Kaye Jack | Director | SELL | 2,645 | $30.01 | $79.4K |
| Jun 3, 2026 | Kaye Jack | Director | M | 2,645 | $0.00 | $0.00 |
| May 8, 2026 | Abi-Saab Walid | Chief Medical Officer | M | 25,000 | $5.59 | $139.8K |
| May 8, 2026 | Abi-Saab Walid | Chief Medical Officer | SELL | 25,000 | $25.10 | $627.5K |
| May 8, 2026 | Abi-Saab Walid | Chief Medical Officer | M | 25,000 | $0.00 | $0.00 |
| Mar 4, 2026 | O'Keefe Kylie | Chief Customer & Strat Officer | A | 31,900 | $0.00 | $0.00 |
| Mar 4, 2026 | Kapusta Matthew C | CEO, Managing Director | A | 70,600 | $0.00 | $0.00 |
| Mar 4, 2026 | Kapusta Matthew C | CEO, Managing Director | A | 113,800 | $0.00 | $0.00 |
| Mar 4, 2026 | Abi-Saab Walid | Chief Medical Officer | A | 67,200 | $0.00 | $0.00 |
| Mar 4, 2026 | Potts Jeannette | Chief Legal Officer | A | 57,200 | $0.00 | $0.00 |
| Mar 4, 2026 | KLEMT CHRISTIAN | Chief Financial Officer | A | 63,900 | $0.00 | $0.00 |
| Mar 4, 2026 | Abi-Saab Walid | Chief Medical Officer | A | 41,700 | $0.00 | $0.00 |
| Mar 4, 2026 | Potts Jeannette | Chief Legal Officer | A | 35,400 | $0.00 | $0.00 |
| Mar 4, 2026 | KLEMT CHRISTIAN | Chief Financial Officer | A | 39,600 | $0.00 | $0.00 |
| Mar 4, 2026 | O'Keefe Kylie | Chief Customer & Strat Officer | A | 19,800 | $0.00 | $0.00 |
| Mar 2, 2026 | Abi-Saab Walid | Chief Medical Officer | SELL | 1,660 | $9.95 | $16.5K |
| Mar 2, 2026 | Potts Jeannette | Chief Legal Officer | SELL | 8,578 | $9.95 | $85.4K |
| Mar 2, 2026 | Kapusta Matthew C | CEO, Managing Director | SELL | 34,437 | $9.95 | $342.6K |
| Mar 2, 2026 | KLEMT CHRISTIAN | Chief Financial Officer | SELL | 12,532 | $9.95 | $124.7K |
| Feb 25, 2026 | Kapusta Matthew C | CEO, Managing Director | SELL | 12,378 | $23.86 | $295.3K |
| Feb 25, 2026 | KLEMT CHRISTIAN | Chief Financial Officer | SELL | 6,217 | $23.86 | $148.3K |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 6 neutral. Avg impact: 4.1/10.
NEUTRAL
144
2/10
Director Jack Kaye filed a Form 144 notice of intent to sell 2,645 ordinary shares of uniQure N.V.,
Jun 3, 2026
BEARISH
PRESS-RELEASE
6/10
uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and reven
May 5, 2026
MIXED
8-K
6/10
uniQure reported Q1 2026 revenue of $3.6M (up from $1.6M YoY) and a net loss of $53.5M ($0.85/share)
May 5, 2026
NEUTRAL
DEFA14A
3/10
uniQure N.V. (QURE) has filed its definitive proxy statement for the 2026 Annual General Meeting, sc
Apr 27, 2026
NEUTRAL
CLUSTER
2/10
Multiple C-suite executives at uniQure N.V. received non-cash stock awards totaling 0 shares at $0 v
Mar 10, 2026
NEUTRAL
CLUSTER
4/10
uniQure's top executives, including the CEO, CFO, CMO, and Chief Legal Officer, were granted stock a
Mar 6, 2026
BEARISH
CLUSTER
7/10
Multiple C-suite executives at uniQure N.V. sold shares in a coordinated open-market transaction on
Mar 6, 2026
NEUTRAL
CLUSTER
3/10
Chief Medical Officer Walid Abi-Saab sold 1,660 shares of QURE in the open market for $16,517. This
Mar 4, 2026
NEUTRAL
CLUSTER
4/10
Two top executives at uniQure — the CEO and CFO — sold shares in a coordinated open-market transacti
Feb 27, 2026
Current analyst consensus: Buy (76% buy). Based on 21 analysts: 6 strong buy, 10 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$38.81 mean target
+46.7% upside
Strong Buy (1.69)
$13.79 Low
$93.57 High
| Metric | Value |
|---|---|
| Current Price | $26.45 |
| Target Low | $13.79 |
| Target Mean | $38.81 |
| Target Median | $34.80 |
| Target High | $93.57 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.69) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next FY 2027-12-31 |
$-2.44 | $-3.39 | $-0.33 | 18.6% | -4.5% | 5↑ 4↓ | $0.1B | 232.2% | 10 |
| Current FY 2026-12-31 |
$-2.99 | $-3.54 | $-2.57 | -2.2% | -0.5% | 5↑ 5↓ | $0.0B | 43.2% | 10 |
| Current Q 2026-06-30 |
$-0.72 | $-0.80 | $-0.65 | -19.9% | +5.7% | 4↑ 0↓ | $0.0B | 3.1% | 10 |
| Next Q 2026-09-30 |
$-0.75 | $-0.92 | $-0.64 | 36.9% | +5.0% | 6↑ 3↓ | $0.0B | 57.7% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.718 | |
| 7d ago | $-0.718 | |
| 30d ago | $-0.761 | +0.043 |
| 60d ago | $-0.757 | +0.040 |
| 90d ago | $-0.812 | +0.095 |
14 analyst firms have rated this stock: 4 upgrades, 3 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Apr 20, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Mar 23, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 11, 2026 | Mizuho | UPGRADE | Neutral | Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 9, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | RBC Capital | UPGRADE | Sector Perform | Outperform |
| Mar 9, 2026 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Mar 3, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Mar 3, 2026 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Mar 3, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Mizuho | DOWNGRADE | Outperform | Neutral |
| Mar 2, 2026 | Cantor Fitzgerald | UPGRADE | Overweight | Neutral |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Peer Perform |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 10, 2026 | HC Wainwright& Co. | REITERATE | Buy | Buy |
| Jan 28, 2026 | Barclays | INITIATE | — | Equal-Weight |
| Dec 11, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Dec 9, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Dec 4, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Nov 12, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Nov 11, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Nov 10, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Nov 4, 2025 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Nov 4, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Nov 4, 2025 | William Blair | DOWNGRADE | Outperform | Market Perform |
| Nov 4, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 3, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Oct 6, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 2, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Sep 25, 2025 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Sep 25, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Sep 25, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Sep 25, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
| Sep 25, 2025 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Sep 25, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Sep 24, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Sep 24, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Sep 24, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 8, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 8, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Sep 5, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 29, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jul 29, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| May 30, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| May 29, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 12, 2025 | Guggenheim | REITERATE | Buy | Buy |
| May 12, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| May 6, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 5 | 0 | 0 | 76% | |
| May 1, 2026 | 6 | 10 | 5 | 0 | 0 | 76% | |
| Apr 1, 2026 | 6 | 10 | 5 | 0 | 0 | 76% | |
| Mar 1, 2026 | 6 | 11 | 5 | 0 | 0 | 77% | |
| Feb 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Jan 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 5, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$QURE -cure to yr RED portfolio?
▲ 0
💬 0
May 15, 2026
short_volume
Short Volume: QURE — 63.0% short (0.4M / 0.6M)
Short: 364,070 | Exempt: 0 | TRF Vol: 578,324 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
QURE Q1 2026 Earnings Before Market Open — 2026-05-12
May 11, 2026
short_interest
FTD: QURE — 65,446 shares ($1.8M) failed to deliver
Settlement: 20260511, Price: $27.66, FTD Value: $1,810,236.36, UNIQURE N V ORD SHS (NLD)
May 5, 2026
earnings
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
<p align="center"><em>~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~</em>
Apr 30, 2026
earnings
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
<p align="center"><em>~ Submission of a UK Marketing Authorization Application for AMT-130 is expected </em><br><em>in the third quarter of 2026 ~</em
Apr 28, 2026
earnings
uniQure to Announce First Quarter 2026 Financial Results
<p align="center"><em>~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~</em></p>
Apr 17, 2026
short_volume
Short Volume: QURE — 61.8% short (0.5M / 0.8M)
Short: 502,741 | Exempt: 306 | TRF Vol: 812,914 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_interest
FTD: QURE — 203,679 shares ($3.2M) failed to deliver
Settlement: 20260324, Price: $15.92, FTD Value: $3,242,569.68, UNIQURE N V ORD SHS (NLD)
Mar 2, 2026
earnings
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
<p align="center"><em>~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerati
Mar 2, 2026
earnings_calendar
QURE Q4 2025 Earnings After Market Close — 2026-03-02
Feb 4, 2026
short_interest
FTD: QURE — 31,851 shares ($0.9M) failed to deliver
Settlement: 20260204, Price: $27.80, FTD Value: $885,457.8, UNIQURE N V ORD SHS (NLD)